Physician profile
R Deva Nathan
NPI 1700987708
$8,464.23
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,407 · 2020: $85.16 · 2021: $2,750 · 2022: $107 · 2023: $512 · 2024: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.65 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,737.02 | 2019-2024 | Akeega, Erleada, Darzalex |
| Glaxosmithkline, LLC. | $2,750.00 | 2021 | |
| Daiichi Sankyo INC. | $400.67 | 2023-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $374.38 | 2019-2024 | Iclusig, Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals Lp | $159.56 | 2019-2024 | Lynparza |
| Jazz Pharmaceuticals INC. | $142.14 | 2019-2024 | |
| Agios Pharmaceuticals, INC. | $140.00 | 2019 | |
| Pfizer INC. | $135.46 | 2019-2024 | |
| Puma Biotechnology, INC. | $121.67 | 2019 | |
| Genentech USA, INC. | $85.83 | 2019-2024 | Lunsumio, Polivy, Columvi |
| E.R. Squibb & Sons, L.L.C. | $73.37 | 2019 | |
| Merck Sharp & Dohme LLC | $58.38 | 2024 | Keytruda, Welireg, Lenvima |
| Amgen INC. | $49.85 | 2019-2020 | |
| Lilly USA, LLC | $44.75 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $36.63 | 2024 | Xermelo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.78 | 2019-2020 | |
| Adc Therapeutics America, INC. | $24.18 | 2024 | |
| Kyowa Kirin, INC. | $20.71 | 2020 | |
| Beigene USA, INC. | $20.49 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $20.41 | 2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $19.80 | 2024 | Clonoseq |
| Dova Pharmaceuticals | $17.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw R Deva Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.